Forest Services
Introduction: Context and Significance
India has administered over 2.2 billion COVID-19 vaccine doses as of May 2024, with an AEFI incidence rate of approximately 0.001% (MoHFW, 2023). Despite this low incidence, only about 10% of reported adverse events following immunization (AEFI) receive formal compensation or redressal (The Hindu, 2024). Currently, India lacks a statutory, no-fault vaccine injury compensation scheme, leading to inconsistent redressal and potential erosion of public trust in vaccination programs. Establishing a dedicated compensation mechanism aligns with global best practices and is critical to sustaining immunization coverage and equitable healthcare delivery.
UPSC Relevance
- GS Paper 2: Health Policies, Constitutional Provisions on Right to Health (Article 21), Public Health Governance
- GS Paper 3: Economic Impact of Health Interventions, Public Health Infrastructure
- Essay: Public Health Systems, Vaccine Hesitancy and Policy Responses
Legal and Constitutional Framework Governing Vaccination in India
The Epidemic Diseases Act, 1897 provides emergency powers for epidemic control but does not address compensation for vaccine injuries. The Drugs and Cosmetics Act, 1940, particularly Chapter IV, regulates vaccine approval and quality but lacks provisions for injury redressal. The National Vaccine Policy 2011 proposed a compensation mechanism but was never fully implemented. The Immunization Technical Support Unit (ITSU) under MoHFW issues guidelines on AEFI surveillance and causality assessment, yet no formal compensation fund exists.
The Supreme Court has interpreted the right to health under Article 21 to imply state responsibility for safe healthcare delivery, including vaccines. The Consumer Protection Act, 2019 classifies healthcare as a service, allowing for consumer claims, but these are often protracted and adversarial, unlike no-fault compensation schemes.
Economic Dimensions of Vaccine Injury Compensation
India's vaccine market was valued at approximately USD 3.5 billion in 2023 with a CAGR of 15% (India Brand Equity Foundation, 2024). The government allocated INR 35,000 crore for COVID-19 vaccination in the 2022-23 budget, underscoring the scale of public investment. Absence of a compensation mechanism risks increased litigation costs and reduced vaccine uptake, threatening program efficiency.
Comparatively, the US National Vaccine Injury Compensation Program (VICP) has disbursed over USD 4 billion since 1988, processing over 7,000 claims annually with a 70% approval rate (HRSA, 2023). This no-fault system reduces litigation burden and sustains high vaccine confidence and coverage above 90%.
Institutional Roles in Vaccine Safety and Compensation
- MoHFW: Policy formulation, implementation, and oversight of immunization programs.
- ICMR: Research and surveillance on vaccine safety and efficacy.
- AEFI Committee: Monitors adverse events, conducts causality assessment, but lacks mandate for compensation disbursal.
- NVBDCP: Implements immunization against vector-borne diseases, dependent on vaccine acceptance.
- CDSCO: Regulates vaccine approval and quality control.
Comparative Analysis: India vs. United States Vaccine Injury Compensation
| Parameter | India | United States |
|---|---|---|
| Legal Framework | No statutory vaccine injury compensation law; AEFI guidelines exist but no compensation fund | National Childhood Vaccine Injury Act, 1986; statutory no-fault compensation program (VICP) |
| Compensation Mechanism | Ad hoc, litigation-based, low formal compensation (<10% AEFI cases compensated) | No-fault claims processed annually (~7,000), 70% approval rate |
| Funding | No dedicated fund; compensation ad hoc and inconsistent | Dedicated Vaccine Injury Compensation Trust Fund financed by vaccine excise tax |
| Impact on Vaccine Confidence | Vaccine hesitancy increased by 15% in regions lacking transparent compensation (Lancet Public Health, 2023) | High vaccine confidence and coverage (>90%) maintained |
Critical Gaps in India's Current Framework
- Absence of a statutory, no-fault compensation scheme delays equitable redressal and increases litigation risks.
- Low public awareness about AEFI compensation rights undermines trust in vaccination programs.
- Inconsistent compensation mechanisms contribute to vaccine hesitancy, risking immunization coverage.
- Lack of dedicated funding and procedural clarity obstructs timely and fair compensation.
Significance and Way Forward
- Establish a statutory, no-fault vaccine injury compensation mechanism with clear procedural guidelines and dedicated funding to ensure equitable and timely redressal.
- Integrate compensation schemes with existing AEFI surveillance and causality assessment frameworks under MoHFW and ITSU.
- Enhance public awareness campaigns to improve transparency and trust, reducing vaccine hesitancy.
- Leverage global best practices, such as the US VICP model, adapting to India's epidemiological and socio-legal context.
- Institutionalize inter-ministerial coordination between MoHFW, CDSCO, ICMR, and legal bodies to streamline compensation and regulatory oversight.
- They provide a no-fault alternative to litigation for vaccine-related injuries.
- The Epidemic Diseases Act, 1897, mandates vaccine injury compensation in India.
- The Consumer Protection Act, 2019, includes healthcare services under the definition of 'service'.
Which of the above statements is/are correct?
- India has a dedicated statutory vaccine injury compensation fund.
- Only about 10% of reported AEFI cases receive formal compensation.
- Vaccine hesitancy has decreased in regions lacking compensation mechanisms.
Which of the above statements is/are correct?
Jharkhand & JPSC Relevance
- JPSC Paper: Paper 2 – Public Health and Welfare; Paper 3 – Governance and Legal Frameworks
- Jharkhand Angle: Jharkhand's immunization coverage is below national average; absence of compensation mechanisms may exacerbate vaccine hesitancy in tribal and rural areas.
- Mains Pointer: Emphasize the role of compensation in building trust in immunization programs, especially in vulnerable Jharkhand populations; suggest state-level coordination with central schemes.
What is the current legal provision for vaccine injury compensation in India?
India currently lacks a statutory vaccine injury compensation scheme. Compensation is handled on an ad hoc basis through litigation or government discretion, with no dedicated fund or clear procedural guidelines.
How does the US National Vaccine Injury Compensation Program function?
Established under the National Childhood Vaccine Injury Act, 1986, the US VICP is a no-fault system funded by a vaccine excise tax. It processes claims through a special court, providing timely compensation without requiring proof of negligence.
What is the role of the AEFI Committee in India?
The AEFI Committee monitors adverse events following immunization, conducts causality assessments, and recommends safety measures but does not have authority to disburse compensation.
Why is a no-fault compensation mechanism preferred over litigation?
No-fault mechanisms reduce adversarial legal processes, ensure faster compensation, lower litigation costs, and improve public trust in vaccines by providing equitable redressal irrespective of fault.
What economic risks does India face without a vaccine injury compensation scheme?
Without compensation, India risks increased litigation costs, reduced vaccine uptake due to hesitancy, and inefficiencies in immunization programs, threatening public health and economic productivity.